Aytu BioPharma, Inc. (AYTU) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.
Analysts estimate Earnings Per Share (EPS) of $-2.49 and revenue of $0.08B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.86 vs est $-2.49 (missed -14.9%). 2025: actual $-2.16 vs est $0.34 (missed -741.6%). Analyst accuracy: 36%.
AYTU Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Aytu BioPharma, Inc. in the past 3 months
EPS Estimates — AYTU
36%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.86
vs Est –$2.49
▼ 12.9% off
2025
Actual –$2.16
vs Est $0.34
▼ 115.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — AYTU
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.081B
vs Est $0.081B
▼ 0.4% off
2025
Actual $0.066B
vs Est $0.069B
▼ 4.2% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
